Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615752 | 1.00 | BRAF (0.44) | BRAFCES2CES1HTTLMNA | |
| SCHEMBL828398 | 0.88 | CES2 (0.44) | BRAFCES2CES1TAS1R3TAS1R1 | |
| SCHEMBL830162 | 0.88 | CES2 (0.44) | BRAFCES2CES1TAS1R3TAS1R1 | |
| SCHEMBL828659 | 0.88 | CES2 (0.44) | BRAFCES2CES1TAS1R3TAS1R1 | |
| SCHEMBL2847108 | 0.82 | LTA4H (0.41) | BRAFCES2CES1TAS1R3TAS1R1 | |
| SCHEMBL2847107 | 0.82 | LTA4H (0.41) | BRAFCES2CES1TAS1R3TAS1R1 | |
| SCHEMBL5762359 | 0.81 | TSHR (0.39) | LMNANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5762364 | 0.81 | TSHR (0.39) | LMNANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4459279 | 0.80 | CES2 (0.42) | CES2CES1HTTNPC1RAB9A | |
| SCHEMBL4459277 | 0.80 | CES2 (0.42) | CES2CES1HTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032141-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-31 | — | — | EP | disclosed |
| US-7763634-B2 | Inhibitors of janus kinases | MERCK & CO., INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090306071-A1 | Inhibitors of Janus Kinases | MERCK SHARP & DOHME LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306071-A1 | Inhibitors of Janus Kinases | JAK2, JAK3, JAK1 | BRAF 412/4885CES2 4855/4885CES1 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.